Matches in SemOpenAlex for { <https://semopenalex.org/work/W1799661034> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W1799661034 endingPage "6" @default.
- W1799661034 startingPage "1032" @default.
- W1799661034 abstract "Topotecan, a water-soluble semisynthetic analogue of camptothecin, is the first topoisomerase I inhibitor to undergo evaluation in pediatric patients with refractory malignancies. A phase I and pharmacokinetic study was performed to determine the maximum tolerated dose (MTD) and dose-limiting toxicities, the incidence and severity of other toxicities, and the pharmacokinetics of topotecan in children. Twenty-nine patients received 42 courses of i.v. topotecan administered as a 24-h continuous infusion every 21 days at doses ranging from 2.0 to 7.5 mg/m2. Dose-related hematological toxicity was the dose-limiting toxicity. Leukopenia, neutropenia, and thrombocytopenia occurred sporadically at the 3.0- to 5.5-mg/m2 dose levels, but at 7.5 mg/m2 4 of 5 patients experienced dose-limiting thrombocytopenia (grade 4) and 2 of 5 had dose-limiting neutropenia (grade 4). No other dose-limiting toxicities were observed. Nausea and vomiting were mild and occurred in < 20 and 10% of patients, respectively. Grade 2 hematuria occurred in one patient. No objective responses were observed. Pharmacokinetic studies revealed a linear relationship between the steady-state topotecan concentration and dose. The mean steady-state concentration at the MTD was 18.2 +/- 3.7 nmol/liter and the total body clearance was 28.3 +/- 6.5 liters/h/m2. Elimination was biexponential with a t1/2 alpha of 14.4 +/- 1.8 min and a t1/2 beta of 2.9 +/- 1.1 h. The recommended starting dose for phase II pediatric trials is 5.5 mg/m2. Although this dose exceeds the MTD identified in heavily pretreated adult patients receiving topotecan on the same schedule, it is less than the MTD for minimally pretreated adult patients. Therefore, dose escalation to 7.5 mg/m2 in phase II pediatric trials should be considered for patients who tolerate treatment well at the 5.5-mg/m2 dose." @default.
- W1799661034 created "2016-06-24" @default.
- W1799661034 creator A5015267921 @default.
- W1799661034 creator A5019914745 @default.
- W1799661034 creator A5020347841 @default.
- W1799661034 creator A5024249524 @default.
- W1799661034 creator A5027416118 @default.
- W1799661034 creator A5027468886 @default.
- W1799661034 creator A5051208048 @default.
- W1799661034 creator A5066722006 @default.
- W1799661034 creator A5075130859 @default.
- W1799661034 creator A5090325707 @default.
- W1799661034 date "1993-03-01" @default.
- W1799661034 modified "2023-09-26" @default.
- W1799661034 title "Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion." @default.
- W1799661034 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8439950" @default.
- W1799661034 hasPublicationYear "1993" @default.
- W1799661034 type Work @default.
- W1799661034 sameAs 1799661034 @default.
- W1799661034 citedByCount "37" @default.
- W1799661034 countsByYear W17996610342016 @default.
- W1799661034 countsByYear W17996610342017 @default.
- W1799661034 crossrefType "journal-article" @default.
- W1799661034 hasAuthorship W1799661034A5015267921 @default.
- W1799661034 hasAuthorship W1799661034A5019914745 @default.
- W1799661034 hasAuthorship W1799661034A5020347841 @default.
- W1799661034 hasAuthorship W1799661034A5024249524 @default.
- W1799661034 hasAuthorship W1799661034A5027416118 @default.
- W1799661034 hasAuthorship W1799661034A5027468886 @default.
- W1799661034 hasAuthorship W1799661034A5051208048 @default.
- W1799661034 hasAuthorship W1799661034A5066722006 @default.
- W1799661034 hasAuthorship W1799661034A5075130859 @default.
- W1799661034 hasAuthorship W1799661034A5090325707 @default.
- W1799661034 hasConcept C112705442 @default.
- W1799661034 hasConcept C126322002 @default.
- W1799661034 hasConcept C178790620 @default.
- W1799661034 hasConcept C185592680 @default.
- W1799661034 hasConcept C2776694085 @default.
- W1799661034 hasConcept C2777063308 @default.
- W1799661034 hasConcept C2779682216 @default.
- W1799661034 hasConcept C2780580376 @default.
- W1799661034 hasConcept C2780852908 @default.
- W1799661034 hasConcept C2780873365 @default.
- W1799661034 hasConcept C2781209748 @default.
- W1799661034 hasConcept C29730261 @default.
- W1799661034 hasConcept C71924100 @default.
- W1799661034 hasConcept C90924648 @default.
- W1799661034 hasConcept C98274493 @default.
- W1799661034 hasConceptScore W1799661034C112705442 @default.
- W1799661034 hasConceptScore W1799661034C126322002 @default.
- W1799661034 hasConceptScore W1799661034C178790620 @default.
- W1799661034 hasConceptScore W1799661034C185592680 @default.
- W1799661034 hasConceptScore W1799661034C2776694085 @default.
- W1799661034 hasConceptScore W1799661034C2777063308 @default.
- W1799661034 hasConceptScore W1799661034C2779682216 @default.
- W1799661034 hasConceptScore W1799661034C2780580376 @default.
- W1799661034 hasConceptScore W1799661034C2780852908 @default.
- W1799661034 hasConceptScore W1799661034C2780873365 @default.
- W1799661034 hasConceptScore W1799661034C2781209748 @default.
- W1799661034 hasConceptScore W1799661034C29730261 @default.
- W1799661034 hasConceptScore W1799661034C71924100 @default.
- W1799661034 hasConceptScore W1799661034C90924648 @default.
- W1799661034 hasConceptScore W1799661034C98274493 @default.
- W1799661034 hasIssue "5" @default.
- W1799661034 hasLocation W17996610341 @default.
- W1799661034 hasOpenAccess W1799661034 @default.
- W1799661034 hasPrimaryLocation W17996610341 @default.
- W1799661034 hasRelatedWork W173197208 @default.
- W1799661034 hasRelatedWork W1799661034 @default.
- W1799661034 hasRelatedWork W1896363289 @default.
- W1799661034 hasRelatedWork W2035090576 @default.
- W1799661034 hasRelatedWork W2070716213 @default.
- W1799661034 hasRelatedWork W2074629895 @default.
- W1799661034 hasRelatedWork W2243955004 @default.
- W1799661034 hasRelatedWork W2285452486 @default.
- W1799661034 hasRelatedWork W2407451361 @default.
- W1799661034 hasRelatedWork W2461579671 @default.
- W1799661034 hasVolume "53" @default.
- W1799661034 isParatext "false" @default.
- W1799661034 isRetracted "false" @default.
- W1799661034 magId "1799661034" @default.
- W1799661034 workType "article" @default.